Device Trial Radar · NCT03605823
Pars Plana Ex-Press Shunt in Vitrectomized Eyes
Last checked: Nov 19, 2026Latest source record: Apr 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Nov 1, 2017
Primary completion
Nov 1, 2019
Study completion Nov 1, 2019
Sponsor
- Lead sponsor
- Cairo UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Implantation of Ex-Press Minishunt via the pars plana in treatment of secondary glaucoma in vitrectomized eyes achieves promising results avoiding complications of other surgical modalities.
Conditions
- Glaucoma Secondary
Interventions
Express Mini shuntDevice
Implantation of Express Mini shunt through pars plana in vitrectomized eyes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Intraocular pressure control (IOP)Time frame: 6 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cairo University
Cairo, Egypt · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.